DOC IT FOUNDATION - Detect Ovarian Cancer In Time

Ovarian cancer is the leading cause of death from gynecologic cancers in the United States, and is the fifth leading cause of cancer death among American women. 

Detect Ovarian Cancer in Time (DOC IT Foundation), is a 501(c)3 organization based in South Florida. Our primary mission is to help find a screening test and cure for ovarian cancer. All proceeds go to medical facilities dedicated to create proper screening for ovarian cancer, because pap smears and regular GYN check-ups unfortunately do not detect it until is too late.

DOC IT was founded by Martha Casado and Susie Casado in 2006. Martha was diagnosed at 47 with stage 4 ovarian cancer and died three years later. Martha fought until the end because of her children and her family. At the same time, she was determined to help other women avoid what she had to go through and make a difference in the lives of women. Martha wanted the world to know what ovarian cancer was and how devastating it is to become a victim of it. Martha died on November 4, 2008, but her will to live and her passion inspired everyone that met her.
To honor Martha and the thousands of women diagnosed with ovarian cancer DOC IT wants to help fund research dedicated to creating a specific screening test to Detect Ovarian Cancer, so that women at risk can find out in time if they have this deadly cancer. At the same DOC IT wants to help women who have been diagnosed with ovarian cancer and have low resources or no insurance.

We are currently looking for WIG Sponsors and Donations for our Cancer Warriors. If you own a wig shop with a healthy flow of customers please contact us! Our partnerships are meant to be lucrative for all parties involved because we believe in Supporting Local & Small Businesses. 

We appreciate your donations. Thank You!

  If you are a WOMAN.... Join the movement!
Make a choice to DOC IT!

You need Flash Player in order to view this.
DOC IT Foundation

How many women get ovarian cancer?
The American Cancer Society estimates for ovarian cancer in the United States for 2015 are:

  • About 21,290 new cases of ovarian cancer.
  • About 14,180 deaths from ovarian cancer.

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. (These statistics don’t count low malignant potential ovarian tumors.)

This cancer mainly develops in older women. About half of the women who are diagnosed with ovarian cancer are 63 years or older. It is more common in white women than African-American women.
As a rule, tumors in the ovary are named for the kinds of cells the tumor started from and whether the tumor is benign or cancerous.

There are 3 main types of tumors:

Epithelial ovarian tumors are derived from the cells on the surface of the ovary. This is the most common form of ovarian cancer and occurs primarily in adults.  Surface epithelial tumors account for ~60% of all ovarian neoplasms and 80-90% of malignant ovarian tumors.
Germ cell tumors are among the least common ovarian tumors, accounting for approximately 10-15% of ovarian tumors. They are derived from the oocytes (eggs). These tumors, like the surface epithelial tumors, can also be benign or malignant. There is, however, no intermediate group. The benign tumors are nearly always mature cystic teratomas or so-called "dermoids" and are successfully treated by the removal of the tumor with preservation of the uninvolved ovarian tissue. No further treatment is necessary. Malignant germ cell tumors require intensive multi agent after their removal. The treatment is completely different from the administered after surgical treatment of a surface epithelial tumor.
Sex cord stromal the least common type of ovarian tumor accounting for approximately 5-10% of ovarian tumors are those derived from the stromal component of the ovary (see diagram). Since hormone production (female sex hormones such as estradiol and progesterone and male hormones such as testosterone, dehydroepiandrosterone [DHEA] and androstenedione) occurs in the stroma, tumors derived from this part of the ovary can be associated with abnormal production of sex steroid hormones. This can lead to abnormal vaginal bleeding in reproductive age and postmenopausal women and precocious puberty in children. Ovarian tumors that produce male sex hormones can cause hirsutism (increased growth of hair on various parts of the body) and in extreme cases, virilization characterized by an increase in body hair, deepening of the voice, balding, increase in muscle mass, and enlargement of the clitoris. (Source: John Hopkins
Having one or more risks for endomorphism or ovarian cancer does not mean you will definitely get the disease.  It means that you may be more likely to get endomorphism or ovarian cancer. Early detection is crucial!

There is good news about early detection!

The great news is that 95% of women diagnosed with early stage ovarian cancer (Stage I) will survive at least five years, and most of them will be cured.
Because early detection is crucial, DOC IT wants to help fund the University of Texas MD Anderson Cancer Center program “Moon Shoots”. MD Anderson Center has chosen to target their ovarian cancer research program among the initial eight to focus on for Moon Shoots. The hospital was ranked the No. 1 hospital for cancer care by US News & World Report’s Best Hospitals survey for nine of the past 11 years, including 2012.

We hope their breakthrough research will, someday soon, develop a blood screening test for ovarian cancer. To learn more you can visit: 

DOC IT also wants to fund FIU (Florida International University) Nanotechnology research. Their initial research was successful in specifically targeting ovarian cancer. 

You can read more here: 

Why we do this?

Our butterfly represents HOPE... 
....for ALL the women currently diagnosed with Ovarian Cancer.

Together we can #DOCIT
Follow us on FB and Twitter